<DOC>
	<DOCNO>NCT03053973</DOCNO>
	<brief_summary>Rationale : Application long-term non-invasive ventilation ( NIV ) chronic obstructive pulmonary disease ( COPD ) patient chronic hypercapnic respiratory failure ( CHRF ) recently show improve outcome . However , mechanism behind improvement unknown . We hypothesize NIV stabilize FEV1 via beneficial effect inflammation repair pathways patient COPD . In present study aim investigate , COPD patient CHRF , 1. change FEV1 3 month nocturnal NIV stable hypercapnic COPD patient compare standard care 2. relationship FEV1 change modification systemic airway inflammation remodelling , lung hyperinflation , airway morphology . 3. predictor favourable response chronic NIV COPD patient CHRF . Study design : multicentre randomise control study investigate effect NIV airway morphology , airway inflammation remodelling hypercapnic COPD patient include control group postpone initiation NIV 3 month . In addition investigate patient demographic , patient disease characteristic systemic airway inflammation predict response chronic NIV severe stable COPD . To , patient follow 6 month NIV initiation . Main study parameters/endpoints : The main endpoint change FEV1 3 month . Furthermore , recognise FEV1 might important patient-related outcome , assess parameter affect health-related quality life 3 6 month .</brief_summary>
	<brief_title>The Effects Nocturnal Non-invasive Ventilation Stable COPD</brief_title>
	<detailed_description>Rationale : Application long-term non-invasive ventilation ( NIV ) chronic obstructive pulmonary disease ( COPD ) patient chronic hypercapnic respiratory failure ( CHRF ) recently show improve outcome apply sufficiently high inspiratory pressure adequate backup breathing frequency ( high-intensity NIV ) . Interestingly , demonstrate nocturnal NIV improve clinical also physiological parameter like arterial carbon dioxide pressure ( PaCO¬2¬ ) force expiratory volume 1 second ( FEV1 ) patient stable COPD . However , mechanism behind improvement unknown . Furthermore , unclear whether improvement lung function influence health-related quality life ( HRQoL ) , utmost goal chronic NIV COPD , baseline patient- ventilatory characteristic important predict long-term beneficial effect . We hypothesize NIV stabilize FEV1 via beneficial effect inflammation repair pathway airways patient COPD . We aim study hypothesis investigate regulation lung function , marker inflammation repair pathway airway biopsy , bronchial wash bronchial nasal epithelium response home mechanical ventilation . The second goal study define phenotype patient COPD , base baseline characteristic biomarkers , marker inflammation , respond NIV therapy improvement lung function HRQoL . Objectives : 1 . To investigate change FEV1 3 month nocturnal NIV stable hypercapnic COPd patient compare standard care 2 . To investigate relationship FEV1 change modification systemic airway inflammation remodelling , lung hyperinflation , airway morphology . 3 . To investigate predictor favourable response chronic NIV COPD patient CHRF . Study design : The study multicentre randomise control study investigate effect NIV airway morphology , airway inflammation remodelling hypercapnic COPD patient include control group postpone initiation NIV 3 month . To measure parameter bronchoscopy bronchial wash bronchial biopsy high-resolution CT-scanning do baseline 3 month . In addition investigate patient demographic , patient disease characteristic systemic airway inflammation predict response chronic NIV severe stable COPD . To , COPD patient initiate NIV centre follow 6 month NIV initiation part present study . Study population : Patients indication NIV ( COPD Global Initiative Obstructive Lung Disease ( GOLD ) III IV PaCO2 &gt; 6.0 kilopascal ( kPa ) stable disease ) Netherlands asked participate . For investigate airway inflammation , ensure safety bronchoscopies , patient severe gas exchange derangement ( i.e . PaCO2 &gt; 8.0 kPa /or partial arterial oxygen pressure ( PaO2 ) &lt; 6.5 kPa rest spontaneous breathe ) , instable cardiac comorbidities exclude . These patient include follow 6 month prospectively NIV initiation , accord protocol , however , without CT-scanning bronchoscopies . Main study parameters/endpoints : The main endpoint change FEV1 3 month . Several marker blood airway inflammation remodel assessed analyse mechanism FEV1 improvement . Furthermore , recognise FEV1 might important patient-related outcome , assess parameter affect health-related quality life 3 6 month . For , parameter total group patient use .</detailed_description>
	<criteria>Indication initiate chronic NIV COPD patient ( GOLD stage III IV : FEV1/ force expiratory volume ( FVC ) &lt; 70 % FEV1 &lt; 50 % predict ; PaCO2 &gt; 6.0 kilopascal ( kPa ) stable condition , mean COPD exacerbation 4 week pH &gt; 7.35 ) Age &gt; 18 year Written inform consent obtain For randomised Inflammation part potential subject meet follow criterion exclude participation study : Oral corticosteroid roflumilast A history lung volume reduction surgery Body mass index ( BMI ) &gt; 35 kg/m2 Obstructive sleep apnoea ( OSA ) ( apnoea/hypopnea index ( AHI ) &gt; 15/hr ) : exclude OSA polygraphy do baseline PaCO2 ≥ 8.0 kPa PaO2 &lt; 6.5 kPa rest without oxygen Instable cardiac comorbidities ( leave ventricular ejection fraction ( LVEF ) &lt; 40 % , instable coronary artery disease , instable heart failure )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>COPD</keyword>
	<keyword>airway inflammation</keyword>
	<keyword>airway remodel</keyword>
	<keyword>health-related auality life</keyword>
	<keyword>forced expiratory volume 1 second</keyword>
</DOC>